Evidence map›Paper›PMID 32249811›Full record

ArticleScientific reports2020

Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.

Mehmet Baysal, Ufuk Demirci, Elif Umit, Hakki Onur Kirkizlar, Emine Ikbal Atli, Hakan Gurkan, Sedanur Karaman Gulsaran, Volkan Bas, Cisem Mail, Ahmet Muzaffer Demir

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mehmet BaysalTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey. drmehmetbaysal@gmail.com.ORCID http://orcid.org/0000-0001-7681-4623
Ufuk DemirciTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
Elif UmitTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
Hakki Onur KirkizlarTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
Emine Ikbal AtliTrakya University Faculty of Medicine, Department of Medical Genetics, Edirne, Turkey.
Hakan GurkanTrakya University Faculty of Medicine, Department of Medical Genetics, Edirne, Turkey.
Sedanur Karaman GulsaranTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
Volkan BasTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
Cisem MailTrakya University Faculty of Medicine, Department of Medical Genetics, Edirne, Turkey.
Ahmet Muzaffer DemirTrakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
Trakya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk assessment in newly diagnosed multiple myeloma patients (NDMM) is the first and the most crucial determinant of treatment. With the utilization of FISH analysis as a part of routine practice, high risk Multiple Myeloma (MM) is defined as having at least one of the mutations related with poor prognosis including; t(4;14) t(14;16), t(14;20), del 17p, p53 mutation, gain 1q and del 1p. M-Smart MM risk stratification guideline by Mayo Clinic has proposed a concept similar to high grade lymphomas. Having two of the high risk genetic abnormalities were defined as double hit MM and having any three as triple hit MM. Based on these definitions which may bring a much more clinically relatable understanding in MM prognosis, we aimed to assess our database regarding these two concepts and their probable significance in terms of outcome and prognosis. We retrospectively evaluated 159 newly diagnosed multiple myeloma patients and their clinical course. Among these patients; twenty-four patients have one high risk determinant and also seven and two patients were classified as double hit MM and triple hit MM respectively. Overall survival (OS) of the patients with double hit MM was 6 months, 32.0 months for patients with single high risk abnormality and 57.0 months for patients with no high risk abnormality. Univariate analysis showed that Double Hit and Triple Hit MM is a predictive of low OS. Hazard Ratio of patients with one high risk abnormality was 1.42, double-hit MM patients was 5.55, and triple-hit MM patients was 7.3. Despite the development of novel drugs and their effects of prolonging survival, the treatment has not been individualized. Understanding the biology of each patient as a unique process will be the success of the treatment. As it is known that some MM patients harbor high risk genetic abnormalities according to FISH analysis, we can continue the argument that some patients bring an even higher risk and that can be defined as double or triple hit MM.

Indexed as

Chromosome AberrationsMutationAgedFemaleHumansMaleMiddle AgedMultiple MyelomaPrognosisRisk AssessmentSurvival Rate

Identifiers

PMID32249811
PMCPMC7136246
OpenAlexW3015022394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.